Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Tobacco smoking dependence in patients with depressive spectrum mental disorders: clinical, pathogenetic, and therapeutic aspects

https://doi.org/10.14412/2074-2711-2019-2-115-120

Full Text:

Abstract

This review considers the clinical and pathogenetic aspects of an association between tobacco smoking dependence and depressive spectrum disorders. The comorbidity of these disorders has been established to be to a large extent determined by their common genetic bases. This association substantially affects the efficiency of treatment. Resistance to anti-nicotine and antidepressant medications is associated precisely with the comorbidity of these diseases. To enhance the efficiency of treatment, it is promising to include non-drug methods into the therapeutic complex. This makes it possible to achieve a gradual reduction in tobacco withdrawal syndrome and to prevent an exacerbation of comorbid depression.

About the Authors

O. I. Speranskaya
V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Ministryof Health
Russian Federation

Olga Ivanovna Speranskaya

23, Kropotkinsy Lane, Moscow 119034



S. A. Trushchelev
V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Ministryof Health
Russian Federation

23, Kropotkinsy Lane, Moscow 119034



Z. I. Storozheva
V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Ministryof Health
Russian Federation

23, Kropotkinsy Lane, Moscow 119034



References

1. Качаева МА, Шпорт СВ, Трущелев СА. Стратегические направления деятельности ВОЗ по охране психического здоровья населения. Российский психиатрический журнал. 2017;(6):10-23.

2. Масленникова ГЯ, Оганов РГ. Медицинский и социально-экономический ущерб, обусловленный курением табака в Российской Федерации: болезни системы кровообращения. Профилактическая медицина. 2011;14(3):19-27.

3. Краснов ВН. Расстройства аффективного спектра. Москва; 2011. 432 с.

4. Смирнов ВК. Клиника и терапия табачной зависимости. Москва; 2000. 95 с.

5. Сперанская ОИ. Табачная зависимость: перспективы исследования, диагностики, терапии: руководство для врачей. Москва; 2011. 166 с.

6. Warburton DM, Mansuco G. Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology (Berl). 1998 Feb;135(3):305-10.

7. Semba J, Mataki Ch, Yamada S, Mamkai M. Antidepressant-like effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry. 1998 Mar 1;43(5):389-91.

8. Reznavi AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry. 2001 Feb 1;49(3): 258-67.

9. Suemaru K, Araki H, Gomita Y. Involvement of neuronal nicotinic receptors in psychiatricdisorders. Nihon Yakurigaku Zasshi. 2002 May; 119(5):295-300.

10. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry. 1990 Jul-Aug; 31(4):350-4.

11. Гарницкая АС. Аффективные расстройства в формировании и клинике табачной зависимости. Автореф. дис. канд. мед. наук. Москва; 1993. 21 c.

12. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry. 1999 Feb;174:173-8.

13. Glassman AH, Heltzer JA, Covey LS, et al. Smoking, smoking cessation and major depression. JAMA. 1990 Sep 26;264(12):1546-9.

14. Dalask GW, Glassman AH, Rivelli S. Mood, major depression and fluoxetine response in cigarette smokers. Am J Psychiatry. 1995 Mar;152(3):398-403.

15. Tsoh JY, Hamfleet GI, Munoz RF, et al. Development of major depressive episode after antismoking therapy. Am J Psychiatry. 2000 Mar;157(3):368-74.

16. Cassidy K, Kotynia R. The relationship between smoking and mental health in older women living in the community. Austral and NZJ Psych. 2004;38(11-12):940.

17. Ritt-Olson A, Unger J, Valente T, et al. The teenager's investigation as mediator of connection between depression and smoking. Substance Use and Misuse. 2005;40(1):79-90.

18. Blazer D, Kessler R, McGonagle K, Swarts S. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survay. Am J Psychiatry. 1994 Jul;151(7):979-86.

19. Covey LS, Glassman AH, Stetner F, Becker J. Effect of history of alcoholism or major depression on smoking cessation. Am J Psychiatry. 1993 Oct;150(10):1546-7.

20. Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation, clonidine and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther. 1993 Dec;54(6):670-9.

21. Killen JD, Fortmann SP, Schatzberg A, et al. Onset of major depression during treatment for nicotine dependence. Addict Behav. 2003 Apr;28(3):461-70.

22. Сперанская ОИ, Смирнов ВК. Особенности терапии табачной зависимости у женщин. Российский психиатрический журнал. 2010;(4):90-4.

23. Сперанская ОИ. Половой диморфизм и курение (аналитический обзор). Сибирский вестник психиатрии и наркологии. 2010; (3):62-5.

24. Wen L, Jiang K, Yuan W, et al. Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism. Mol Neurobiol. 2016 Jan;53(1): 472-84.

25. Wang Q, Li S, Pan L, et al. Association between variants in nicotinic acetylcholine receptor genes and smoking cessation in a Chinese rural population. Am J Addict. 2016 Jun;25(4):297-300. doi: 10.1111/ajad.12383.

26. Robinson JD, Versace F, Lam CY, et al. Cinciripini The CHRNA3 rs578776 Variant is Associated with an Intrinsic Reward Sensitivity Deficit in Smokers. Front Psychiatry. 2013 Sep 23;4:114. doi: 10.3389/fpsyt.2013.00114. eCollection 2013.

27. Adrian M, Kiff C, Glazner C, et al. Examining gene-environment interactions in comorbid depressive and disruptive behavior disorders using a Bayesian approach. J Psychiatr Res. 2015 Sep;68:125-33. doi: 10.1016/j.jpsychires.2015.06.004.

28. Сперанская ОИ, Сторожева ЗИ, Бочкарев ВК, Ковалева МЕ. Клинико-генетическая предикция фармакорезистентности у лиц с табачной зависимостью. Вопросы наркологии. 2017;(11):21-32.

29. Gong L, He C, Yin Y, et al. Nonlinear modulation of interacting between COMT and depression on brain function. Eur Psychiatry. 2017 Sep;45:6-13. doi: 10.1016/j.eurpsy.2017.05.024.

30. Slopien R, Rozycka A, Slopien A, et al. The genetic background of climacteric symptoms in women during menopause. Clin Exp Obstet Gynecol. 2016;43(4):495-9.

31. Cao Y, Lin X, Chen L, et al. The CatecholO-Methyltransferase and Dopamine Transporter Genes Moderated the Impact of Peer Relationships on Adolescent Depressive Symptoms: A Gene-Gene-Environment Study. J Youth Adolesc. 2018 Nov;47(11):2468-2480. doi: 10.1007/s10964-018-0925-3. Epub 2018 Sep 21.

32. Da Silva BS, Rovaris DL, Schuch JB, et al. Effects of corticotropin-releasing hormone receptor 1 SNPs on major depressive disorder are influenced by sex and smoking status. J Affect Disord. 2016 Nov 15;205:282-288. doi: 10.1016/j.jad.2016.08.008.

33. Nishizawa D, Kasai S, Hasegawa J, Ikeda K. Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genomewide and subsequent association studies. Mol Brain. 2015 Aug 20;8:50. doi: 10.1186/s13041015-0142.

34. Wang C, Wang Q, Ji B, et al. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci. 2018 Jun 28;11:220. doi: 10.3389/fnmol.2018.00220. eCollection 2018.

35. MacGregor F, Alexoff D, Shea C, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996 Feb 22; 379(6567):733-6.

36. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology. 2007;28(1):182-95.

37. Kirch D, Gerhardt GA, Shelton RS. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin Neuropharmacol. 1987 Aug;10(4):376-83.

38. Hall SM, Reus VI, Munos RF, Sees KL. Nortriptyline and cognitive-behavioural therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998 Aug;55(8):683-90.

39. Kotlyar M, Golging M, Hatsukami DK, Jamerson BD. Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacoterapy. 2001;21(12):1530-1548.

40. Пантелеева ГП, Артюх ВВ, Абрамова ЛИ, Олейчик ИВ. Велаксин (венлафаксин) в лечении эндогенных депрессий: клиническое действие и переносимость. Фарматека. 2007;(Прил. Психиатрия):8-14.

41. Hughes JP. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2002;(1): CD000031. doi: 10.1002/14651858.CD000031

42. Литвинов ЕВ. Исследование мотивации к курению и ее коррекции у студентов с ХОБЛ с помощью терапии прозаком. Вестник Воронежского государственного технического университета. 2005;1(10):186-8.

43. Литвинов ЕВ. Сравнительная оценка функционального состояния ВНС у курящих и некурящих студентов с ХОБЛ, разделенных по показаниям алекситимичности, на основе исследования ВСР с применением дыхательной пробы. Вестник новых медицинских технол. 2006;13(1):45-7.

44. Elbe D, Bezchlibnyk-Butler K, Virani A, Procyshyn RM, editors. Clinical Handbook of Psychotropic Drugs for Children and Adolescents. 3rd edition. Hogrefe Publishing; 2014. 368 p.

45. Сперанская ОИ. Немедикаментозные методы в лечении табачной зависимости. В кн.: Иванец НН, Анохина ИП, Винникова МА, редакторы. Наркология: национальное руководство. 2-е изд. Москва; 2016. С. 281-7.

46. Суховская ОА, Куликов НВ. Лечение никотиновой зависимости при сердечно-сосудистых заболеваниях, с позиции доказательной медицины. Российский кардиологический журнал. 2019;(2):86-91.

47. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebocontrolled clinical trial. Lancet. 2016 Jun 18;387(10037):2507-20. doi:10.1016/S01406736(16)30272-0.

48. Суховская ОА, Смирнова МА. Совместное применение варениклина и когнитивно-поведенческой терапии методом телефонного консультирования при оказании помощи в отказе от табакокурения. Медицинский совет. 2015;(11):109-12.

49. Ziedonis D, Das S, Larkin C. Tobacco use disorder and treatment: new challenges and opportunities. Dialogues Clin Neurosci. 2017 Sep;19(3):271-280.

50. Denison E, Underland V, Mosdњl A, Vist GE. Cognitive therapies for smoking cessation: a systematic review. Report 2017. Oslo: The Norwegian Institute of Public Health; 2017.


For citation:


Speranskaya O.I., Trushchelev S.A., Storozheva Z.I. Tobacco smoking dependence in patients with depressive spectrum mental disorders: clinical, pathogenetic, and therapeutic aspects. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):115-120. (In Russ.) https://doi.org/10.14412/2074-2711-2019-2-115-120

Views: 30


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)